Drug profile

The FDA adverse-event record for Douxo Chlorhexidine Micro-Emulsion Spray

36 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Douxo Chlorhexidine Micro-Emulsion Spray. See the species affected, top reactions, and outcomes below.

36
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
18
Application site erythema - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Douxo Chlorhexidine Micro-Emulsion Spray

Administration Routes

TopicalUnknownOphthalmic

Species Affected

Dog 35
Human 1

Most Affected Breeds

Crossbred Canine/dog 6
Retriever - Golden 3
Dog (unknown) 3
Shepherd Dog - German 2
Pekingese 2
Terrier (unspecified) 2
Retriever - Labrador 2
Terrier - Yorkshire 1
Havanese 1
Pointing Dog - Hungarian Short-haired (Vizsla) 1

Most Reported Reactions

Application site erythema 18
Application site pruritus 4
Application site reddening 3
Application site inflammation 3
Diarrhoea 2
Peeling skin 2
Emesis 2
Loose stool 2
Application site irritation 2
Application site swelling 2
Application site pain 2
Lack of efficacy - NOS 2

Outcome Breakdown

Recovered/Normal
17 (47.2%)
Ongoing
14 (38.9%)
Outcome Unknown
5 (13.9%)

Douxo Chlorhexidine Micro-Emulsion Spray Adverse Event Insights

36 reports name Douxo Chlorhexidine Micro-Emulsion Spray; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Douxo Chlorhexidine Micro-Emulsion Spray. Administration routes: Topical, Unknown, Ophthalmic.

By species: Dog (35 reports), Human (1 reports). By breed: Crossbred Canine/dog (6), Retriever - Golden (3), Dog (unknown) (3).

Leading clinical signs: Application site erythema (18), Application site pruritus (4), Application site reddening (3), Application site inflammation (3). Outcome, 36 coded reports: Recovered/Normal leads at 47.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.